<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844918</url>
  </required_header>
  <id_info>
    <org_study_id>17506</org_study_id>
    <secondary_id>I8F-JE-GPHZ</secondary_id>
    <nct_id>NCT04844918</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease</brief_title>
  <acronym>SURMOUNT-J</acronym>
  <official_title>Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about tirzepatide in participants with&#xD;
      obesity disease. The study will also measure how Tirzepatide affects body weight with a&#xD;
      low-calorie diet and increased physical activity. The study will last around 72 Weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">August 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who Achieve ≥5% Body Weight Reduction</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieve ≥5% Body Weight Reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Body Weight</measure>
    <time_frame>Baseline, 72 Weeks</time_frame>
    <description>Percent Change in Body Weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had Improvement in Obesity-related Health Problems</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of participants who had improvement in at least 2 obesity-related health problems in participants with a baseline body mass index (BMI) ≥27 and &lt;35 kilogram per square meter (kg/m²) or improvement in at least 1 obesity-related health problems in participants with a baseline BMI ≥35 kg/m²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose (Only for Participant with Impaired Glucose Tolerance [IGT] at Baseline)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in OGTT 2-hr Glucose (Only for Participants with IGT at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Glucose (Only for Participants with IGT at Baseline)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Fasting Glucose (Only for Participants with IGT at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Lipids [Triglycerides (TG)] (Only for Participants with hyperlipidemia at Baseline)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Fasting Lipids TG (Only for Participants with hyperlipidemia at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hepatic Fat Fraction (HFF) (only for participants diagnosed as Non-alcoholic Fatty Liver Disease [NAFLD] by Magnetic Resonance Imaging (MRI) at Baseline)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in HFF (only for participants diagnosed as NAFLD by MRI at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Improvements of IGT (Only for Participants with IGT at Baseline)</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieved Improvements of IGT (Only for Participants with IGT at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Improvements of Hyperlipidemia (Only for Participants with Hyperlipidemia at Baseline)</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieved Improvements of Hyperlipidemia (only for participants with hyperlipidemia at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Improvements of NAFLD (only for participants who are diagnosed as NAFLD by Magnetic Resonance Imaging (MRI) at Baseline)</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieved Improvements of NAFLD (only for participants who are diagnosed as NAFLD by MRI at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥10% body weight reduction</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieve ≥10% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥15% body weight reduction</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieve ≥15% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Absolute Body Weight</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Absolute Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BMI</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Visceral Adipose Tissue (VAT)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in VAT will be collected by single slice imaging at the umbilicus level in a supine position using computerized tomography (CT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Subcutaneous Adipose Tissue (SAT)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in SAT will be collected by single slice imaging at the umbilicus level in a supine position using CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in VAT/SAT Ratio</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in VAT/SAT Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve VAT &lt;100 square centimeter (cm²) from Baseline (only for participants with VAT≥100 cm2 at Baseline)</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of Participants Who Achieve VAT &lt;100 cm² from Baseline (only for participants with VAT≥100 cm2 at Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Waist Circumference</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Waist Circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Insulin</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Fasting Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Systolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Diastolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in SF-36v2 Acute Form Physical Functioning Domain Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Change in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Change in IWQOL-Lite-CT Physical Function score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>Change from Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">261</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Tirzepatide Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide Regimen A administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide Regimen B administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide Regimen A</arm_group_label>
    <arm_group_label>Tirzepatide Regimen B</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a BMI of greater than or equal to ≥27 kg/m² and &lt;less than 35 kg/m² with at least&#xD;
             2 obesity-related health problems or ≥35 kg/m² with at least 1 obesity-related health&#xD;
             problems. Health problems are IGT, hyperlipidemia, or NAFLD.&#xD;
&#xD;
          -  Have a history of at least 1 self-reported unsuccessful dietary effort to lose body&#xD;
             weight.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have diabetes.&#xD;
&#xD;
          -  Acute or chronic liver disease other than NAFLD.&#xD;
&#xD;
          -  Have a self-reported change in body weight &gt;5 kg within 3 months prior to screening.&#xD;
&#xD;
          -  Have or plan to have endoscopic and/or device-based therapy for obesity or have had&#xD;
             device removal within the last 6 months.&#xD;
&#xD;
          -  Have renal impairment measured as estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             mL/min/1.73 m2, calculated by Japanese Society of Nephrology coefficient-modified&#xD;
             Chronic Kidney Disease-Epidemiology equation during screening.&#xD;
&#xD;
          -  Have a known clinically significant gastric emptying abnormality.&#xD;
&#xD;
          -  Have had a history of chronic or acute pancreatitis.&#xD;
&#xD;
          -  Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 micro units per&#xD;
             milliliter (μIU/mL) at screening.&#xD;
&#xD;
          -  Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or&#xD;
             syndromic forms of obesity.&#xD;
&#xD;
          -  Have a history of significant active or unstable major depressive disorder or other&#xD;
             severe psychiatric disorder within the last 2 years.&#xD;
&#xD;
          -  Have a cardiovascular condition within 3 months prior to randomization&#xD;
&#xD;
          -  Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine&#xD;
             Neoplasia Syndrome type 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLilly (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLilly (1-877-295-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kohnodai Hospital, National Center for Global Health and Med</name>
      <address>
        <city>Ichikawa</city>
        <state>Chiba</state>
        <zip>272-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masatoshi Imamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Matsuyama Hospital</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hiroaki Miyaoka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Takai Internal Medicine Clinic</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masahiko Takai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Motomachi Takatsuka Naika Clinic</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yoji Takatsuka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Tobu Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2308765</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Takamasa Ichijo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Suita Hospital</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>5640013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Toshihide Shima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OCROM Clinic</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Satoshi Inoue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Takatsuki Red Cross Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shizuka Kaneko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Adult Disease, Asahi Life Foundation</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yukiko Onishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Arihiro Kiyosue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Chiseikai Tokyo Center Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hirotaka Nagashima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuwa Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yasushi Fukushima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Central Hospital</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>108-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Toshiyuki Takahashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shimokitazawa Tomo Clinic</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>155-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Tomofumi Murakami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miho Clinic</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141 0032</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Otoya Miho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai ToCROM Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Osamu Matsuoka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamagata Tokushukai Hospital</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Isoji Sasagawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC Nishiumeda Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yoshimitsu Yamasaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism and Nutrition Disorder</keyword>
  <keyword>Obesity Related Health Problems</keyword>
  <keyword>Obesity Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

